These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The current status of PET scanning with respect to schizophrenia. Sedvall G Neuropsychopharmacology; 1992 Aug; 7(1):41-54. PubMed ID: 1388021 [TBL] [Abstract][Full Text] [Related]
24. Dopamine D2-receptor imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier? Verhoeff NP; Visser WH; Ferrari MD; Saxena PR; van Royen EA Cephalalgia; 1993 Oct; 13(5):325-9. PubMed ID: 8242725 [TBL] [Abstract][Full Text] [Related]
25. IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome. Oertel WH; Schwarz J; Tatsch K; Arnold G; Gasser T; Kirsch CM Adv Neurol; 1993; 60():519-24. PubMed ID: 8420182 [TBL] [Abstract][Full Text] [Related]
26. In vivo studies of [125I]iodobenzamide and [11C]iodobenzamide: a ligand suitable for positron emission tomography and single photon emission tomography imaging of cerebral D2 dopamine receptors. Wong DF; Wilson AA; Chen C; Minkin E; Dannals RF; Ravert HT; Sanchez-Roa P; Villemagne V; Wagner HN Synapse; 1992 Nov; 12(3):236-41. PubMed ID: 1481143 [TBL] [Abstract][Full Text] [Related]
27. Imaging of D2 dopamine receptors of patients with Parkinson's disease using single photon emission computed tomography and iodobenzamide I 123. Laulumaa V; Kuikka JT; Soininen H; Bergström K; Länsimies E; Riekkinen P Arch Neurol; 1993 May; 50(5):509-12. PubMed ID: 8489408 [TBL] [Abstract][Full Text] [Related]
28. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT. Schelosky L; Hierholzer J; Wissel J; Cordes M; Poewe W Mov Disord; 1993 Oct; 8(4):453-8. PubMed ID: 8232354 [TBL] [Abstract][Full Text] [Related]
29. Dopamine D2 receptor brain imaging in the neonatal period using 123I-IBZM SPECT. Tranquart F; Saliba E; Zimmer L; Barantin L; Lanneau M; Guilloteau D; Baulieu JL J Nucl Med; 1999 Dec; 40(12):2126-7. PubMed ID: 10616897 [No Abstract] [Full Text] [Related]
30. The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism. Schreckenberger M; Hägele S; Siessmeier T; Buchholz HG; Armbrust-Henrich H; Rösch F; Gründer G; Bartenstein P; Vogt T Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1128-35. PubMed ID: 15042325 [TBL] [Abstract][Full Text] [Related]
31. Imaging of dopamine transporters and D2 receptors in vascular parkinsonism: a report of four cases. Plotkin M; Amthauer H; Quill S; Marzinzik F; Klostermann F; Klaffke S; Kivi A; Gutberlet M; Felix R; Kupsch A J Neural Transm (Vienna); 2005 Oct; 112(10):1355-61. PubMed ID: 15719156 [TBL] [Abstract][Full Text] [Related]
32. Initial experience with SPECT examinations using [123I]IBZM as a D2-dopamine receptor antagonist in Parkinson's disease. Cordes M; Henkes H; Laudahn D; Bräu H; Kramp W; Girke W; Hierholzer J; Eichstädt H; Felix R Eur J Radiol; 1991; 12(3):182-6. PubMed ID: 1830273 [TBL] [Abstract][Full Text] [Related]
33. Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease. Chalon S; Emond P; Bodard S; Vilar MP; Thiercelin C; Besnard JC; Guilloteau D Synapse; 1999 Feb; 31(2):134-9. PubMed ID: 10024010 [TBL] [Abstract][Full Text] [Related]
34. 123I-IBZM SPECT: reconstruction methodology and results in parkinsonism and dystonia. Berding G; Gratz KF; Kolbe H; Meyer GJ; Dengler R; Knoop BO; Hundeshagen H Nuklearmedizin; 1994 Oct; 33(5):194-9. PubMed ID: 7997377 [TBL] [Abstract][Full Text] [Related]
35. No direct correlation between behaviorally active doses of the dopamine D2 agonist LY 171555 and displacement of [123I]IBZM as measured with SPECT in MPTP monkeys. Vermeulen RJ; Drukarch B; Verhoeff NP; Goosen C; Sahadat MC; Wolters EC; van Royen EA; Stoof JC Synapse; 1994 Jun; 17(2):115-24. PubMed ID: 7916490 [TBL] [Abstract][Full Text] [Related]
36. [Cerebral SPECT with iodine-123 IBZM in patients with extrapyramidal system disorders: the evaluation of its sensitivity in therapy with dopaminergic drugs]. Hierholzer J; Castelli L; Cordes M; Schelosky L; Poewe W; Felix R Radiol Med; 1996 Mar; 91(3):207-10. PubMed ID: 8628932 [TBL] [Abstract][Full Text] [Related]
37. [PET study of dopamine metabolism and dopamine D2 receptor in juvenile parkinsonism]. Tanji H; Nagasawa H; Itoh M; Itoyama Y Nihon Rinsho; 1997 Jan; 55(1):89-94. PubMed ID: 9014428 [TBL] [Abstract][Full Text] [Related]
38. Dual-radiotracer translational SPECT neuroimaging. Comparison of three methods for the simultaneous brain imaging of D Tsartsalis S; Tournier BB; Habiby S; Ben Hamadi M; Barca C; Ginovart N; Millet P Neuroimage; 2018 Aug; 176():528-540. PubMed ID: 29723640 [TBL] [Abstract][Full Text] [Related]